Today: 19 May 2026
Browse Category

NASDAQ:BEAM 20 October 2025 - 13 January 2026

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics shares rose about 5% to $28.24 by early afternoon Tuesday after Bank of America raised its price target to $45 and reaffirmed a buy rating. The stock touched $30.49 before paring gains. A new SEC filing showed Chief Legal Officer Christine Bellon sold 1,254 shares on Dec. 31 in an automatic transaction tied to tax withholding.
6 January 2026
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

ARK Invest bought 521,867 Pinterest shares across three funds after the stock fell over 20% on weak holiday-quarter guidance. The firm also added CRISPR Therapeutics and Beam Therapeutics shares earlier in the week. ARK sold 105,576 Roku shares and 56,095 Robinhood shares, and reduced its position in Teradyne. Pinterest projected Q4 revenue below consensus, citing softer ad spending and tougher competition.
6 November 2025
········
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics shares rose about 17% to $30 after the FDA granted RMAT and Orphan Drug designations to its lead gene-editing programs, BEAM-101 and BEAM-302. Early trial data showed BEAM-302 raised protective AAT levels and BEAM-101 produced durable increases in fetal hemoglobin. Wall Street’s average 12-month price target is $45–46, implying roughly 70–80% upside.
21 October 2025
··
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····

Stock Market Today

  • Pinterest Shares Drop 6.6% Amid Legal Challenges; Analyst Ratings Mixed
    May 19, 2026, 4:32 PM EDT. Pinterest (NYSE:PINS) shares fell 6.6% to $18.61 on Tuesday, with trading volume down 58% from average. The decline follows class action lawsuits alleging investor misinformation about business resilience, increasing legal and reputational risk. While legal proceedings are at an early stage, they highlight ongoing scrutiny. Wall Street analysts show mixed views: Wells Fargo raised its target to $28 with an overweight rating, while Piper Sandler maintained neutral at $26. Others, like Wedbush and Loop Capital, lowered targets and ratings. Sixteen analysts rate Pinterest as Buy, eighteen Hold, and one Sell, with a consensus target of $27.40. The stock trades below its 50-day ($19.29) and 200-day ($22.61) moving averages, with a market cap of $10.49 billion and a P/E ratio of 39.01.

Latest articles

NextNRG shares double as buying spikes, but the numbers show a catch

NextNRG shares double as buying spikes, but the numbers show a catch

19 May 2026
NextNRG shares more than doubled Tuesday, closing at $0.8288 and rising to about $0.91 after hours, after reporting April revenue up 56% to $9.4 million, its highest on record. Gross margin for April reached 8.3%. Trading volume topped 344 million shares, with market value near $135 million. The company posted a first-quarter net loss of $10.8 million and had $208,048 in cash at March 31.
AST SpaceMobile Shares Whipsaw in Volatile Trading

AST SpaceMobile Shares Whipsaw in Volatile Trading

19 May 2026
AST SpaceMobile shares closed up 2.2% at $88.75 Tuesday after volatile trading between $78.68 and $90.88. Investors shifted focus from last week’s earnings miss to the company’s plan to launch 45 BlueBird satellites this year, with two already en route to Cape Canaveral. First-quarter revenue rose to $14.7 million, but net loss widened to $191 million. AST reported $3.46 billion in cash at quarter’s end.
Warby Parker Shares Slip After AI Glasses Reveal; Investors React

Warby Parker Shares Slip After AI Glasses Reveal; Investors React

19 May 2026
Warby Parker shares fell Tuesday after the company unveiled its first “Intelligent Eyewear” with Google and Samsung, but did not disclose pricing or a launch date. The stock traded at $25.51, with volume triple the average. The new AI-powered glasses are set for a fall launch and will support multiple prescriptions and lens options. First-quarter revenue rose 8.3% to $242.4 million, while gross margin slipped to 54%.
Go toTop